search
Back to results

Role of Nitric Oxide in Cirrhosis: Relationship With Systemic Hemodynamics, Renal Function, Vasoactive Systems and Endotoxemia

Primary Purpose

Cirrhosis, Liver Cirrhosis

Status
Unknown status
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
N-monomethyl-L-arginine
Sponsored by
National Center for Research Resources (NCRR)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cirrhosis

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Patients with compensated cirrhosis without previous history of ascites or edema Cirrhotic patient with ascites without renal failure Cirrhotic patients with ascites with functional renal failure Age and sex-matched healthy subjects

Sites / Locations

  • 4200 E. Ninth Ave., Box C281Recruiting

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
April 11, 2000
Last Updated
June 23, 2005
Sponsor
National Center for Research Resources (NCRR)
search

1. Study Identification

Unique Protocol Identification Number
NCT00005107
Brief Title
Role of Nitric Oxide in Cirrhosis: Relationship With Systemic Hemodynamics, Renal Function, Vasoactive Systems and Endotoxemia
Study Type
Interventional

2. Study Status

Record Verification Date
December 2003
Overall Recruitment Status
Unknown status
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
National Center for Research Resources (NCRR)

4. Oversight

5. Study Description

Brief Summary
This study is to determine whether a compound, nitric oxide, made within the body, is the factor responsible for the changes in blood pressure and renal (kidney) functions that may occur during the course of cirrhosis. Patients with cirrhosis (liver scarring which causes poor liver function) will be eligible to participate. A group of healthy subjects will also be studied to compare the effects of the treatment to patients with cirrhosis and to confirm safety. A total number of 30 patients with cirrhosis and 10 healthy subjects will be enrolled in the study.
Detailed Description
Upon admission, the patients will be physically examined and started on a special diet that will continue throughout the study. During the first four days of the study, the weight, heart rate and blood pressure of the patients will be measured every morning and 24-hour urine will be collected. On day 5, intravenous lines will be inserted in the patient's arms. One line will be used to draw blood samples and the other line will be used to infuse medications. Blood samples will be taken to measure liver and kidney function, nitric oxide, and other hormones that participate in the regulation of body fluids and blood pressure. Inulin and paraaminohippurate infusions (substances used routinely in the study of kidney function) will be started and blood and urine samples will then be taken at periodic intervals. Ninety minutes after the initiation of inulin and PAH infusions, L-NMMA (an investigational drug expected to increase the blood pressure and improve the kidney functions) will be infused. Blood and urine samples will be collected every 30 minutes. These procedures will take 4 hours. A total amount of about 10 tablespoons of blood will be drawn during the study. The patients will be discharged from the GCRC the next morning and restarted on their regular medications.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cirrhosis, Liver Cirrhosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Masking
None (Open Label)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
N-monomethyl-L-arginine

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients with compensated cirrhosis without previous history of ascites or edema Cirrhotic patient with ascites without renal failure Cirrhotic patients with ascites with functional renal failure Age and sex-matched healthy subjects
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Chiraq Parikh, M.D.
Phone
1-303-266-0771
Facility Information:
Facility Name
4200 E. Ninth Ave., Box C281
City
Denver
State/Province
Colorado
ZIP/Postal Code
80262
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Learn more about this trial

Role of Nitric Oxide in Cirrhosis: Relationship With Systemic Hemodynamics, Renal Function, Vasoactive Systems and Endotoxemia

We'll reach out to this number within 24 hrs